Akebia Therapeutics, Inc.

NASDAQ:AKBA

Biotechnology

Healthcare
$0.41 +0.49%

+$0.01 today

Market cap
$113.54M
Beta
0.25
P/E (TTM)
-13.3
EPS (TTM)
-$0.08
52W Low $0.82High $4.08

Volume 7.09M

Average 4.03M

AKBA Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Akebia Therapeutics, Inc.NASDAQ: AKBA

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 267.05M shares rose 13.4% year over year, behind the +21.2% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.6% from the prior quarter. Over 3 fiscal years it compounded at +12.1% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +13.4% toward the trailing-twelve-month pace of +21.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
267.05M+0.6% QoQ
Last fiscal yearDec 2025
257.16M+21.9% YoY
LTMMar 2026
264.94M+21.2% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.4%——
1 year+21.9%——
3-year CAGR+12.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
257.16M USD
Year-over-year change
+21.9%
4-year CAGR
+11.6%

Weighted Avg Shares vs competitors

How AKBA compares with its peers on the latest reported figures

  • AKBA's LTM Mar 2026 weighted avg shares of 264.94M shares is the highest of the 10 companies compared; the peer median is 59.51M shares.
  • Its year-over-year change of +21.2% is the 3rd highest of 9, against a peer median of +10.8%.
  • Over three fiscal years its annual growth of +12.1% compares with a peer median of +18.2%.
AKBA Competitors Peer median
Weighted Avg Shares for AKBA and competitors
Company Period LTM YoY 3-year CAGR
AKBAAkebia Therapeutics, Inc.LTM Mar 2026264.94M +21.2%+12.1%
GOSSGossamer Bio, Inc.LTM Mar 2026229M +1.1%+39.3%
CMPXCompass Therapeutics, Inc.LTM Mar 2026161.95M +17.8%+14.5%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 202691.34M +41.8%+29.6%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 202682.39M +23.5%+19.3%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 202659.51M +7.9%+21.4%
ZVRAZevra Therapeutics, Inc.LTM Mar 202656.11M +13.7%+17.1%
PRTAProthena Corporation plcLTM Mar 202653.8M -0.0%+4.4%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 202552.2M ——
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202618.08M +2.4%+1.4%
Peer median (excluding AKBA) 59.51M+10.8%+18.2%

Competitors are the stored peer set for AKBA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue211.65M292.48M194.62M160.18M236.2M
Cost of Revenue81.49M22.5M74.15M63.18M39.46M
Gross Profit130.16M269.99M120.47M97M196.73M
Gross Margin61.5%92.3%61.9%60.6%83.3%
Research & Development147.85M165.99M63.08M37.65M62.36M
Selling, General & Admin174.14M138.6M100.23M106.55M107.48M
Operating Expenses394.66M350.77M166.73M147.48M173.24M
Depreciation & Amortization37.97M37.7M37.63M37.5M1.27M
EBITDA(189.91M)3.06M(8.27M)(13.72M)21.73M
EBITDA Margin-89.7%1.0%-4.2%-8.6%9.2%
Operating Income(264.5M)(80.78M)(46.26M)(50.47M)23.5M
Operating Margin-125.0%-27.6%-23.8%-31.5%9.9%
Interest Income00000
Interest Expense19.94M15.69M6.03M18.19M24.18M
Other Income / Expenses(17.52M)(13.45M)(5.67M)(18.94M)(27.22M)
Income Before Tax(282.02M)(94.23M)(51.93M)(69.41M)(3.72M)
Pre-Tax Margin-133.3%-32.2%-26.7%-43.3%-1.6%
Income Tax Expense00001.62M
Net Income(282.02M)(94.23M)(51.93M)(69.41M)(5.35M)
Net Margin-133.3%-32.2%-26.7%-43.3%-2.3%
EPS (Basic)(1.48)(0.58)(0.28)(0.33)(0.02)
EPS (Diluted)(1.48)(0.58)(0.28)(0.33)(0.02)
Weighted Avg Shares165.95M182.78M187.47M210.95M257.16M
Weighted Avg Shares (Diluted)165.95M182.78M187.47M210.95M257.16M

Akebia Therapeutics, Inc.

NASDAQ:AKBA

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.